Back to Journals » Infection and Drug Resistance » Volume 11

Better drugs for Lyme disease: focus on the spirochete

Authors Stricker RB, Middelveen MJ

Received 11 June 2018

Accepted for publication 20 July 2018

Published 7 September 2018 Volume 2018:11 Pages 1437—1439

DOI https://doi.org/10.2147/IDR.S176831

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 4

Editor who approved publication: Professor Suresh Antony


Video abstract presented by Raphael Stricker.

Raphael B Stricker,1 Marianne J Middelveen2

1Union Square Medical Associates, San Francisco, CA, USA; 2Atkins Veterinary Services, Calgary, AB, Canada

Abstract: Twenty-five years ago, the AIDS epidemic was wreaking havoc around the world. Although “HIV denialists” threatened to undermine research efforts to combat the epidemic, development of targeted antiviral therapy eventually provided effective treatment for the disease. Now the Lyme disease epidemic is wreaking havoc around the world, and “Lyme denialists” are undermining efforts to combat the epidemic. Drawing on our experience with the AIDS epidemic, there is a significant need to develop targeted therapy to control the Lyme disease epidemic.

Keywords: HIV/AIDS, Lyme disease, Borrelia burgdorferi, tick-borne disease, designer drugs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]